Lafadofensine
Appearance
Clinical data | |
---|---|
Drug class | Serotonin–norepinephrine–dopamine reuptake inhibitor |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C16H16F2N2 |
Molar mass | 274.315 g·mol−1 |
3D model (JSmol) | |
| |
|
Lafadofensine (INN ), also known as (3S)-N,N-bis(4-fluorophenyl)pyrrolidin-3-amine, is a drug described as an antidepressant which has not been marketed at this time.[1][2][3] It is said to act as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI).[1] The drug was first described by 2010[4] and its INN was proposed by 2021.[5]
See also
[edit]References
[edit]- ^ a b World Health Organization (2024). "Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024" (PDF). World Health Organization. p. 102. Retrieved 21 October 2024.
-fensine norepinephrine, serotonin, dopamine reuptake inhibitors brasofensine (76), diclofensine (44), lafadofensine (126), liafensine (109), nomifensine (24), perafensine (44), tesofensine (89)
- ^ "LAFADOFENSINE". Inxight Drugs. Retrieved 21 October 2024.
- ^ "Lafadofensine". PubChem. Retrieved 21 October 2024.
- ^ AU 2006/244851B2, Akazawa K, Amada N, Ito N, Kurimura M, Masumoto T, Matsuzaki T, Menjo Y, Miyamura S, Morita C, Nakajima S, Ohashi S, Sakata Y, Sakurai Y, Sasaki H, Shinohara T, Sugino H, Tai K, Taira S, Takemura N, Tomoyasu T, Watanabe A, Yamashita J, "N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors", issued 10 June 2010, assigned to Otsuka Pharmaceutical Co Ltd.
- ^ "Proposed INN: List 126 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 35 (4). 2021.